ASTar® System Commercialization

About Q-Linea

Q-linea is a publicly traded infection diagnostics company with a commercialized, FDA-cleared product, the ASTar® system. Its core achievement is the development of a rapid phenotypic AST platform that reduces diagnostic time from up to 48 hours to about 6 hours, directly addressing the critical unmet need in sepsis management and antimicrobial stewardship. The company's strategy focuses on expanding the commercial footprint of ASTar, generating robust clinical and health-economic evidence, and pursuing regulatory clearances for new assays and geographies. Q-linea aims to establish its technology as a new standard of care in hospital microbiology labs globally.

Therapeutic Areas